Key terms
About INAB
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest INAB news
Apr 12
1:45am ET
Promising Preclinical Data Underpins Buy Rating for IN8bio’s nsCAR Platform
Mar 19
2:21am ET
Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN), Intuitive Surgical (ISRG) and IN8bio (INAB)
Mar 18
7:10am ET
IN8bio initiated with a Buy at Laidlaw
Mar 12
4:17pm ET
IN8bio initiated with a Buy at JonesResearch
Mar 12
4:15pm ET
Buy Recommendation Based on IN8bio’s Promising γ δ T Cell Therapy Developments and Positive Clinical Trial Outcomes
Feb 14
8:15am ET
IN8bio announces publication on gamma-delta t cell therapy
Feb 13
5:33am ET
Analysts Are Bullish on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), CymaBay Therapeutics (CBAY)
Jan 12
5:17pm ET
IN8bio files to sell 42.7M shares of common stock for holders
No recent press releases are available for INAB
INAB Financials
Key terms
Ad Feedback
INAB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
INAB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
